Hep Email Update FDA Approves Vemlidy for Children With Hepatitis B Tenofovir alafenamide is safe and effective for pediatric patients ages 6 and up. Daily Aspirin Reduces Liver Fat in People With MASLD People who took low-dose aspirin every day were more likely than placebo recipients to lose at least 30% of liver fat. FDA Authorizes New COVID-19 Prevention for Immunocompromised People Pemgarda (pemivibart) is a monoclonal antibody that helps protect people who may not respond well to COVID vaccines. Advertisement FDA Approves First-Ever Drug for Fatty Liver Disease People who used resmetirom (Rezdiffra) in a late-stage clinical trial experienced both MASH resolution and fibrosis improvement. What Is Fatty Liver Disease? (MASLD and MASH) Learn the latest about fatty liver. What Is Hepatitis C? Get the basics! Advertisement Science News FDA Approves Vemlidy for Children With Hepatitis B FDA Authorizes New COVID-19 Prevention for Immunocompromised People Daily Aspirin Reduces Liver Fat in People With MASLD FDA Approves First-Ever Drug for Fatty Liver Disease Newsfeed Rapid Vaccine Rollout Prevented a Hepatitis A Outbreak at LA County Jail Cancer Advocates Celebrate Anniversary of the Affordable Care Act UNAIDS Urges Scaling Up of Evidence-Based Services to Address the Transmission of HIV and Viral Hepatitis Among People Who Use Drugs FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight Science News FDA Approves Vemlidy for Children With Hepatitis B FDA Authorizes New COVID-19 Prevention for Immunocompromised People Daily Aspirin Reduces Liver Fat in People With MASLD FDA Approves First-Ever Drug for Fatty Liver Disease Newsfeed Rapid Vaccine Rollout Prevented a Hepatitis A Outbreak at LA County Jail Cancer Advocates Celebrate Anniversary of the Affordable Care Act UNAIDS Urges Scaling Up of Evidence-Based Services to Address the Transmission of HIV and Viral Hepatitis Among People Who Use Drugs FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@hepmag.com. Please remember to add update@hepmag.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: